The effects of castration on vasoactive intestinal polypeptide (VIP) immunostaining in human corpus cavernosum (CC) and the relationship between VIP immunostaining and erectile function were studied in patients with localised prostate cancer who had (Group 1 ¼ castrated) or had not (Group 2 ¼ control) undergone 3-month neoadjuvant chemical castration before radical prostatectomy. Evaluation of erectile function included medical and sexual history, physical examination, and measurement of total serum testosterone. CC biopsies were taken at the end of radical prostatectomy and samples immunostained with anti-human VIP antibody. Specific staining was quantified by image analysis and expressed in arbitrary units (AU). Chemical castration induced erectile function deterioration in 70% of patients due to loss of sexual interest and confidence in the ability of having an erection rather than reduced ability of obtaining sexually induced erections. Average VIP content was 34.5 AU in Group 1 and 39 AU in Group 2 and this difference was not statistically significant. Chemical castration does not influence VIP immunostaining of human CC, suggesting that VIP is not an androgen-dependent neuromediator of penile erection and that it can be responsible for sexually induced erections in castrated patients.
Introduction
The nonadrenergic noncholinergic nervous system is the principal pathway of penile erection with nitric oxide (NO) and vasoactive intestinal polypeptide (VIP) functioning as its neurotransmitters. [1] [2] [3] [4] Both substances are potent vasodilators and the administration of their antagonists blocks the vasorelaxation induced by electrical stimulation of penile smooth muscle cells both in vitro and in vivo.
1-4 In the human corpus cavernosum (CC), more than 50% of the perivascular nerve fibres and more than 90% of the trabecular nerve fibres stain positive for both nitric oxide synthase (NOS) and VIP, suggesting that the two neurotransmitter are comediators of penile erection. 5 NO initiates penile erection by dilating the helicine arteries and relaxing the trabecular meshwork, but its vasorelaxant effect lasts a few seconds. 6 VIP, which has a half-life of more than 10 min, 7 is likely to be responsible for maintenance of relaxation. 8 Whether or not VIP is able to induce neurogenic relaxation of human CC smooth muscle cells in the absence of NO initiation has not been established.
It has recently been shown that castration reduces NOS expression in the nerve fibres of the rat CC and that subsequent androgen supplementation restores NOS expression, 9 suggesting that NO is an androgen-dependent neurotransmitter. Considering that NOS and VIP are colocalised and probably function as comediators, the present study aimed to determine whether chemical castration reduces VIP immunostaining of nerve fibres of human CC and, consequently, the relationship between VIP immunostaining and penile erection in castrated patients.
Materials and methods
Patients undergoing radical prostatectomy for localised prostate cancer and who had already been randomised to receive radical prostatectomy or 3-month neoadjuvant chemical castration (LHRH agonist plus antiandrogen) plus radical prostatectomy were given full and clear information on this study, including aim, methods, possible complications and possible clinical implications (according to Helsinki Declaration, 1975) . Those interested to enter the study gave a written consent.
Evaluation of erectile function included detailed medical and sexual history, physical examination, measurement of total serum testosterone and dihydrotestosterone (DHT) the day before radical prostatectomy. At the beginning of this study, the International Index of Erectile Function (IIEF) had not been introduced yet. However, our questions on sexual history were practically those of the IIEF-5 10 and therefore we considered it adequate to turn our questions into IIEF-5 scores.
Four CC biopsies, two per CC, were taken at the end of radical prostatectomy. After having retracted the penile foreskin, a 18-G Topnotcht automatic core biopsy needle (Boston Scientific, Boston, Massachusetts, USA) was fired into the corpora through the coronal sulcus. Then, 1 min manual compression was applied to avoid haematomas.
The samples were placed in 4% buffered formalin and immunostained using anti-human VIP antibody. Specific staining was quantified by image analysis (Optilab Pro 2.6, GRAFTEK, Villanterio, Italy) and expressed in arbitrary units (AU).
Statistical significance was calculated using Student's t-test, with significance set at Po0.05.
Results
Of the 33 patients undergoing radical prostatectomy in the study period, 26 entered the study. However, six patients with diabetes mellitus (DM) were excluded, as DM has been suggested to impair VIP expression.
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Of the remaining 20 patients, 10 had received neoadjuvant chemical castration (Group 1 ¼ castrated) castrated) and 10 had not (Group 2 ¼ noncastrated).
In Group 1, the mean age was 68 y (range 53-75 y). In the interview taken before chemical castration, six patients claimed normal erectile function (IIEF-5 score 421), three claimed mild erectile dysfunction (ED) (score 17-21) and one severe ED (score 5-7), whereas in the interview taken after radical prostatectomy, two patients claimed normal erectile function (score 421), five claimed mild ED (score 17-21), two claimed mild to moderate ED (score 12-16) and one severe ED (score 5-7). However, the seven patients with reduced erectile function after medical castration mainly complained of loss of libido and loss of confidence in the ability of having an erection (IIEF-5 question 1). Average IIEF-5 scores were 19.475.1 before castration and 16.774.5 after castration and this difference was statistically significant (Po0.001, paired t-test). Average total serum testosterone (Table 1) was 0.2 ng/ml (n.v. 2.9-11.5 ng/ml), whereas average serum DHT was 29 ng/dl (n.v. 25-100 ng/dl).
In Group 2, the mean age was 65 y (range 53-74 y). In the interview taken before radical prostatectomy, seven patients claimed normal erectile function (score 421), two claimed mild to moderate ED (score 12-16) and one moderate ED (score 8-11). Average total serum testosterone (Table 1 ) was 4.3 ng/ml, whereas average serum DHT was 44 ng/dl.
There were no complications from CC biopsies. Average VIP content was 34.5 AU in Group 1 (range 10-60) and 39 AU in Group 2 (range 10-70); this difference was not statistically significant (P ¼ 0.325, paired t-test). VIP content was o20 AU only in the two patients with IIEF-5 score below 12 (moderate-severe ED), but the number is too small to come to any conclusion.
Discussion
Chemical or surgical castration have been reported to cause loss of sexual interest in more than 80% of patients and loss of sexually induced erections in almost 60% of patients, 12 suggesting that maintenance of testosterone levels is important for sexual activity.
The main effect of testosterone is central stimulation of sexual interest, and it seems to be mediated by metabolites (eg oestrogens after the peripheral conversion of testosterone by aromatase) acting either directly or by modifying neural androgen metabolism. 13 Another central effect of testosterone involves stimulation of NOS in the medial preoptic area, which leads to increased NO production, increased dopamine release and consequent activation of the dopaminergic erectile pathway. 14 It has recently been shown 9 that testosterone also has a peripheral effect involving regulation of NOS expression in the nerve fibres of CC. In a rat model, NOS expression in the CC was reduced by castration and restored by subsequent androgen supplementation, suggesting that NO is an androgen-dependent neuromediator of penile erection. 9 This peripheral effect may be responsible for loss of erection associated with chemical or surgical castration. However, the findings that more than 40% of chemically or surgically castrated patients maintain the ability of obtaining sexually induced erections, 12 that patients chemically castrated before male-tofemale gender reassignment surgery maintain sexually induced erections but not nocturnal erections, 15 that testosterone depletion in young hypogonadal men is associated with reduced sexual interest and activity but normal erectile response to erotic stimuli 16 and that testosterone supplementation enhances rigidity and frequency of nocturnal erections but has no effect on sexually induced Effects of VIP on penile erection L Cormio et al erections [17] [18] support the existence of other androgen-independent neuromediators of penile erection.
The present study confirms that castration is associated with reduced sexual function which is due, to a great extent, to loss of sexual interest and loss of confidence in the ability of having an erection (central effects of testosterone) and, to a less extent, to reduced ability of obtaining sexually induced erections (peripheral effects of testosterone on CC NOS expression). To our knowledge, this is the first study demonstrating that castration does not influence VIP immunostaining of human CC. Our immunohistochemical findings are well in agreement with quantitative (RT-PCR estimation of VIP mRNA) findings of a recent study in rat, 19 and suggest that VIP is an androgen-independent neurotransmitter and could be responsible for sexually induced erections in castrated patients. The androgen independence of this neurotransmitter is further supported by fact that VIP-induced vasodilatation is mediated by cAMP pathway, 7 whereas NO-induced vasodilatation is mediated by the cGMP pathway. In conclusion, the present study provides the information that the VIP-cAMP pathway of penile erection is not androgen-dependent and could, consequently, be responsible for the occurrence of sexually induced erections in castrated patients. Androgen deficiency is a major problem in the ageing male and may contribute to the age-related increase in ED shown by epidemiological studies worldwide. 20 It has been shown that ageing reduces NOS expression but not VIP expression in CC nerve fibres, 19, 21 suggesting that VIP is also age-independent. Knowledge of such androgen-and age-independent pathway of penile erection may be of relevance in developing new treatment options for age-and hypogonadism-related ED. Effects of VIP on penile erection L Cormio et al
